Ligand id: 6809

Name: docetaxel

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: docetaxel

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 15
Hydrogen bond donors 5
Rotatable bonds 14
Topological polar surface area 224.45
Molecular weight 807.35
XLogP 4.57
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Docetaxel is an anti-mitotic compound used mainly for the treatment of breast, ovarian, prostate, and non-small cell lung cancers.
Preliminary results from a recent clinical trial (June 2014) which compared hormone-depleting therapy alone with hormone-depleting therapy plus docetaxel in newly diagnosed metastatic prostate cancer patients, indicates that the combination treatment increases median survival after more than two years and delays cancer progression by around one year (unpublished results).
Mechanism Of Action and Pharmacodynamic Effects
Docetaxel reversibly binds to microtubules with high affinity, hyper-stabilising their structure and limiting the flexibility of the cell's cytoskeleton, thus compromising cell growth, division and ultimately viability.